MTVA heads into its May 18 earnings print carrying one of the most expensive borrow costs in the biotech universe — a signal that short-side pressure, while not dominant by position size, is punishingly costly to maintain.
Borrowing MTVA shares costs nearly 200% annualised. The cost to borrow has held above 199% for weeks, easing only modestly from a peak above 270% in mid-April. That cost sits well above what most short sellers can sustain for long, and it tells a specific story: the lending pool is under real pressure despite short interest remaining small in absolute terms. Short interest registers at just 0.34% of the free float — low by any standard — but the sheer expense of maintaining that position reflects how little stock is available to borrow. Utilization has pulled back to around 22%, off a 52-week high of 100%, meaning the current borrow market is looser than its tightest point — but the triple-digit cost to borrow persists regardless. The stock itself has given back 21% over the past month, trading at $1.19, with another 10.5% shed in the past week alone. Options data predates 2026 and cannot be treated as current.
The bull and bear cases for MTVA are starkly divided on the clinical credibility of DA-1726, the company's obesity-focused dual agonist. Bulls point to early readouts showing an average body weight loss of 4.3% by Day 26, a maximum reduction of 6.3% from baseline, and meaningful reductions in waist circumference — data that, if it holds, positions the company within the crowded but lucrative cardiometabolic space. Bears counter that the Phase 1 data for DA-1726 has disappointed on some metrics, that the MASH combination therapy programme for DA-1241 faces challenges, and that funding constraints and competitive pricing dynamics could limit the addressable market even if the science advances. HC Wainwright is the only firm on record, maintaining a Buy rating while cutting its target from $40 to $20 in late March — a halving of the target that signals sharply reduced conviction even from the lone bull. The $19 mean target sits well above the $1.19 current price, but given the recency of that cut and the absence of any competing analyst coverage, this data point should be read cautiously rather than as a directional signal.
Past earnings reactions have been volatile and predominantly negative. Three of the four most recent events produced declines: a 6.2% drop in a single session in late March 2026, a 2.4% fall on April 2, and a sharp 9.2% slide in November 2025 that deepened to a 34% loss over five days. The single positive reaction — a 13.8% jump in November 2025 — snapped back but could not offset the broader pattern of post-print weakness. Ownership is heavily concentrated: Korean strategic investors Dong-A ST and Dong-A Socio Holdings together hold more than 34% of shares, with no meaningful change in their reported positions since January. That concentration limits the effective float and likely contributes to the elevated borrow cost.
The May 18 print is therefore a test of whether MTVA's clinical data has advanced enough to reverse a pattern of post-earnings selling — and whether DA-1726's early efficacy signals can withstand the scrutiny of a market that has already marked the stock down sharply into the event.
See the live data behind this article on ORTEX.
Open MTVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
